Skip to main content

BriaCell Therapeutics Corp.

corporate_fare Company Profile

BriaCell Therapeutics Corp.

BCTX·NASDAQ·Life Sciences·CIK 0001610820

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care. Immunotherapies harness the body's own immune system to recognize and destroy cancer cells. The company is advancing its Bria-IMT™ targeted immunotherapy in combination with an immune checkpoint inhibitor (Retifanlimab®) in a pivotal Phase 3 study in metastatic breast cancer (ClinicalTrials.gov: NCT06072612). Bria-IMT™ is under Fast Track Designation by the U.S. Food and Drug Administration (FDA), intended to accelerate review of novel treatments addressing unmet medical needs. Positive completion of the pivotal study, following FDA review, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer. BriaCell has reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer, with median overall survival of 13.3 months for the Phase 3 sequence in BriaCell's metastatic breast cancer patients versus median overall survival reported in the literature and in its Phase 2 study of the Bria-IMT™ combination study with Retifanlimab®. Additionally, BriaCell reported median overall survival of 16.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor in patients treated with the Phase 3 formulation since 2022 (post-COVID). A completed Bria-IMT™ Phase 1/2 combination study with Retifanlimab® (an anti-PD1 antibody manufactured by Incyte Corporation) confirmed tolerability and early-stage efficacy (ClinicalTrials.gov: NCT03328026). BriaCell's Phase 1/2 study of Bria-OTS™, the company's personalized off-the-shelf immunotherapy, in metastatic breast cancer is ongoing (ClinicalTrials.gov: NCT06471673). The first patient treated with 4 inoculations of cells (single agent) demonstrated complete resolution of a lung metastasis. BriaCell is developing Bria-OTS™ and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for numerous types of cancer.

BriaCell Therapeutics Corp. (NASDAQ:BCTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for BCTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for BCTX spans 10-K, 8-K, 10-Q, 424B5.

Recent high-impact activity:

  • BriaCell 10-K: $34.9M FY2026 Loss, Going Concern Doubt Reaffirmed
  • BriaCell Subsidiary BriaPro Files Interim Financials, Reveals $3M Credit Facility from Parent Amid Going Concern
  • BriaCell Partners for Scalable Microneedle Delivery of Phase 3 Cancer Drug Bria-IMT
  • Going Concern Warning Reiterated Amidst Increased Losses and Dilutive $4.7M Offering
  • BriaCell Therapeutics Closes $4.7M Public Offering, Issues Placement Agent Warrants

Financial Snapshot

Fiscal year ended July 31, 2026
Net Income
-$34.9M
Diluted EPS
-$6.97
Op. Cash Flow
-$28.65M
Free Cash Flow
-$28.78M
Operating Income
-$36.05M
Cash & Equivalents
$9.85M
Debt / Equity
0.00×
Shares Outstanding
8.71M sh
Source: 10-K · filed 2026-10-28 · accession 0001493152-26-049041

Short Interest & Short Volume

12.47 days to cover

FINRA reported short interest of 807,641 shares in BCTX as of the October 30, 2026 settlement, a 2.3% increase from the prior period — about 12.5 days to cover at its recent average daily volume. On November 20, 2026, 43.7% of BCTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)807,641 shares as of October 30, 2026
Change vs prior period▲ 2.3%
Days to cover12.47 at avg daily volume of 64,791
Daily short volume (FINRA facilities)43.7% of 76,249 shares on November 20, 2026
5-day average short volume60.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for BCTX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-09.

1 recent capital raise

Capital Raise Finalized · Significant Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$3.1 +1.31% today
52-week range · as of 2026-10-28 $2.6 – $13.8
Market cap
$26.72M
Volume
109.7K (1.7× avg)
3-mo avg 64.4K
Live data · 2026-11-22 05:24 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BCTX - Latest Insights

BCTX
Oct 28, 2026, 4:43 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.50
Real-time Price: $3.10 info
Change: -$0.400 (-11%) info
Market Cap: $26.721M info
BCTX
Jun 26, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.06
Real-time Price: $3.10 info
Change: +$0.040 (+1%) info
Market Cap: $26.721M info
BCTX
Jun 25, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.33
Real-time Price: $3.10 info
Change: -$0.230 (-7%) info
Market Cap: $26.721M info
BCTX
Jun 09, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.07
Real-time Price: $3.10 info
Change: +$0.030 (+0.98%) info
Market Cap: $26.721M info
BCTX
Jun 02, 2026, 9:32 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.37
Real-time Price: $3.10 info
Change: -$0.270 (-8%) info
Market Cap: $26.721M info
BCTX
Jun 02, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.27
Real-time Price: $3.10 info
Change: -$0.170 (-5%) info
Market Cap: $26.721M info
BCTX
Jun 02, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.39
Real-time Price: $3.10 info
Change: -$0.290 (-9%) info
Market Cap: $26.721M info
BCTX
Jun 01, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.28
Real-time Price: $3.10 info
Change: -$0.180 (-5%) info
Market Cap: $26.721M info
BCTX
May 31, 2026, 7:59 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.70
Real-time Price: $3.10 info
Change: -$0.600 (-16%) info
Market Cap: $26.721M info
BCTX
May 26, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.47
Real-time Price: $3.10 info
Change: -$0.370 (-11%) info
Market Cap: $26.721M info
BCTX
May 22, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.67
Real-time Price: $3.10 info
Change: -$0.570 (-16%) info
Market Cap: $26.721M info
BCTX
May 15, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $3.10 info
Change: -$1.000 (-24%) info
Market Cap: $26.721M info
BCTX
May 14, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $3.10 info
Change: -$1.00 (-24%) info
Market Cap: $26.721M info
BCTX
May 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $3.10 info
Change: -$1.08 (-26%) info
Market Cap: $26.721M info
BCTX
Apr 20, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.50
Real-time Price: $3.10 info
Change: -$1.40 (-31%) info
Market Cap: $26.721M info
BCTX
Mar 31, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.25
Real-time Price: $3.10 info
Change: -$1.15 (-27%) info
Market Cap: $26.721M info
BCTX
Mar 18, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.55
Real-time Price: $3.10 info
Change: -$1.45 (-32%) info
Market Cap: $26.721M info
BCTX
Mar 10, 2026, 5:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.88
Real-time Price: $3.10 info
Change: -$0.780 (-20%) info
Market Cap: $26.721M info
BCTX
Feb 20, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $3.10 info
Change: -$0.820 (-21%) info
Market Cap: $26.721M info
BCTX
Feb 12, 2026, 4:00 PM EST
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $4.10
Real-time Price: $3.10 info
Change: -$0.995 (-24%) info
Market Cap: $26.721M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets